Loading stock data…
ACIU
$2.84+0.07 (+2.53%)
Market ClosedLast close May 13
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AC Immune SA in the Healthcare sector is trading at $2.84. Wall Street consensus targets $9.00 (4 analysts), implying a +216.9% move over the next 12 months. The stock is currently 29% below its 52-week high of $4.00, remaining 2.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +216.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$2.84
Potential Downside
0%
Whystock Fair Value$2.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$311.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-163.27%
Volume
Today's trading volume
246,748
Recent News
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of +5.00% and +42.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Leerink Says AC Immune (ACIU) Eli Lilly Tau Program Amendment Is Great News
AC Immune SA (NASDAQ:ACIU) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 7, 2026, Leerink analyst Marc Goodman said AC Immune SA (NASDAQ:ACIU) amending its collaboration with Eli Lilly for the Morphomer Tau program is “great news,” highlighting continued interest in targeting intracellular Tau for early Alzheimer’s prevention. […]
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.